These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 10935147)
1. Effect of glycoprotein IIb/IIIa inhibitors on the individual components of composite endpoints used in clinical trials of unstable angina and non-Q-wave myocardial infarction. Brown DL; Fann CS; Chang CJ Cardiovasc Drugs Ther; 2000 Jun; 14(3):253-8. PubMed ID: 10935147 [TBL] [Abstract][Full Text] [Related]
2. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors. Adgey AA Eur Heart J; 1998 Apr; 19 Suppl D():D10-21. PubMed ID: 9597518 [TBL] [Abstract][Full Text] [Related]
3. Selection of glycoprotein IIb/IIIa inhibitors for upstream use in patients with diabetes experiencing unstable angina or non-ST segment elevation myocardial infarction. What have we learned in the last 10 years? Silva MA; Gandhi PJ J Clin Pharm Ther; 2004 Dec; 29(6):497-510. PubMed ID: 15584937 [TBL] [Abstract][Full Text] [Related]
4. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Boersma E; Harrington RA; Moliterno DJ; White H; Théroux P; Van de Werf F; de Torbal A; Armstrong PW; Wallentin LC; Wilcox RG; Simes J; Califf RM; Topol EJ; Simoons ML Lancet; 2002 Jan; 359(9302):189-98. PubMed ID: 11812552 [TBL] [Abstract][Full Text] [Related]
6. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators N Engl J Med; 1998 May; 338(21):1488-97. PubMed ID: 9599103 [TBL] [Abstract][Full Text] [Related]
7. International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina. The PARAGON Investigators. Platelet IIb/IIIa Antagonism for the Reduction of Acute coronary syndrome events in a Global Organization Network. Circulation; 1998 Jun; 97(24):2386-95. PubMed ID: 9641689 [TBL] [Abstract][Full Text] [Related]
8. Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial. Stone GW; Bertrand ME; Moses JW; Ohman EM; Lincoff AM; Ware JH; Pocock SJ; McLaurin BT; Cox DA; Jafar MZ; Chandna H; Hartmann F; Leisch F; Strasser RH; Desaga M; Stuckey TD; Zelman RB; Lieber IH; Cohen DJ; Mehran R; White HD; JAMA; 2007 Feb; 297(6):591-602. PubMed ID: 17299194 [TBL] [Abstract][Full Text] [Related]
9. Effects of glycoprotein IIb/IIIa inhibition on clinical stabilization parameters in patients with unstable angina and non-Q-wave myocardial infarction. Okmen E; Cakmak M; Tartan Z; Cam N Heart Vessels; 2003 Jul; 18(3):117-22. PubMed ID: 12955426 [TBL] [Abstract][Full Text] [Related]
10. Safety and preliminary efficacy of one month glycoprotein IIb/IIIa inhibition with lefradafiban in patients with acute coronary syndromes without ST-elevation; a phase II study. Akkerhuis KM; Neuhaus KL; Wilcox RG; Vahanian A; Boland JL; Hoffmann J; Baardman T; Nehmiz G; Roth U; Klootwijk AP; Deckers JW; Simoons ML; Eur Heart J; 2000 Dec; 21(24):2042-55. PubMed ID: 11102255 [TBL] [Abstract][Full Text] [Related]
12. Implications of upstream glycoprotein IIb/IIIa inhibition and coronary artery stenting in the invasive management of unstable angina/non-ST-elevation myocardial infarction: a comparison of the Thrombolysis In Myocardial Infarction (TIMI) IIIB trial and the Treat angina with Aggrastat and determine Cost of Therapy with Invasive or Conservative Strategy (TACTICS)-TIMI 18 trial. Sabatine MS; Morrow DA; Giugliano RP; Murphy SA; Demopoulos LA; DiBattiste PM; Weintraub WS; McCabe CH; Antman EM; Cannon CP; Braunwald E Circulation; 2004 Feb; 109(7):874-80. PubMed ID: 14757697 [TBL] [Abstract][Full Text] [Related]
13. Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease. Kong DF; Califf RM; Miller DP; Moliterno DJ; White HD; Harrington RA; Tcheng JE; Lincoff AM; Hasselblad V; Topol EJ Circulation; 1998 Dec 22-29; 98(25):2829-35. PubMed ID: 9860783 [TBL] [Abstract][Full Text] [Related]
14. Sex differences in major bleeding with glycoprotein IIb/IIIa inhibitors: results from the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) initiative. Alexander KP; Chen AY; Newby LK; Schwartz JB; Redberg RF; Hochman JS; Roe MT; Gibler WB; Ohman EM; Peterson ED; Circulation; 2006 Sep; 114(13):1380-7. PubMed ID: 16982940 [TBL] [Abstract][Full Text] [Related]
15. Small molecule glycoprotein IIb/IIIa receptor inhibitors as upstream therapy in acute coronary syndromes: insights from the TACTICS TIMI-18 trial. Cannon CP J Am Coll Cardiol; 2003 Feb; 41(4 Suppl S):43S-48S. PubMed ID: 12644340 [TBL] [Abstract][Full Text] [Related]
16. Attenuation of rebound ischemia after discontinuation of heparin therapy by glycoprotein IIb/IIIa inhibition with eptifibatide in patients with acute coronary syndromes: observations from the platelet IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial. Lauer MA; Houghtaling PL; Peterson JG; Granger CB; Bhatt DL; Sapp SK; Simoons ML; Harrington RA; Topol EJ; Lincoff AM; Circulation; 2001 Dec; 104(23):2772-7. PubMed ID: 11733393 [TBL] [Abstract][Full Text] [Related]
17. Effect of platelet glycoprotein IIb/IIIa receptor blockade with tirofiban on adverse cardiac events in women with unstable angina/non-ST-elevation myocardial infarction (PRISM-PLUS Study). Huynh T; Theroux P; Snapinn S; Wan Y; Am Heart J; 2003 Oct; 146(4):668-73. PubMed ID: 14564321 [TBL] [Abstract][Full Text] [Related]
18. Invasive versus conservative strategies in unstable angina and non-Q-wave myocardial infarction following treatment with tirofiban: rationale and study design of the international TACTICS-TIMI 18 Trial. Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy. Thrombolysis In Myocardial Infarction. Cannon CP; Weintraub WS; Demopoulos LA; Robertson DH; Gormley GJ; Braunwald E Am J Cardiol; 1998 Sep; 82(6):731-6. PubMed ID: 9761082 [TBL] [Abstract][Full Text] [Related]
19. Design and methodology of the PURSUIT trial: evaluating eptifibatide for acute ischemic coronary syndromes. Platelet Glycoprotein IIb-IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. Harrington RA Am J Cardiol; 1997 Aug; 80(4A):34B-38B. PubMed ID: 9291244 [TBL] [Abstract][Full Text] [Related]
20. Glycoprotein IIb/IIIa receptor blockade improves outcomes in diabetic patients presenting with unstable angina/non-ST-elevation myocardial infarction: results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) study. Théroux P; Alexander J; Pharand C; Barr E; Snapinn S; Ghannam AF; Sax FL Circulation; 2000 Nov; 102(20):2466-72. PubMed ID: 11076818 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]